BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 885.72M | 874.84M | 599.82M | 557.51M | 503.49M |
| Total Other Revenue | -- | 11.29M | 18.64M | 19.41M | 20.45M |
| Total Revenue | 885.72M | 874.84M | 599.82M | 557.51M | 503.49M |
| Cost of Revenue | 207.02M | 183.16M | 189.15M | 186.65M | 179.79M |
| Gross Profit | 678.70M | 691.68M | 410.67M | 370.86M | 323.70M |
| SG&A Expenses | 356.46M | 344.37M | 333.31M | 315.40M | 289.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 563.48M | 527.53M | 522.46M | 502.05M | 469.05M |
| Operating Income | 322.24M | 347.30M | 77.36M | 55.46M | 34.44M |
| Income Before Tax | -454.18M | 267.39M | -6.62M | -32.19M | -51.18M |
| Income Tax Expenses | 3.81M | 3.53M | 2.16M | 3.52M | 2.29M |
| Earnings from Continuing Operations | -457.98 | 263.86 | -8.78 | -35.71 | -53.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -457.98M | 263.86M | -8.78M | -35.71M | -53.47M |
| EBIT | 322.24M | 347.30M | 77.36M | 55.46M | 34.44M |
| EBITDA | 326.46M | 350.79M | 80.79M | 58.51M | 37.47M |
| EPS Basic | -1.73 | 1.25 | -0.04 | -0.17 | -0.26 |
| Normalized Basic EPS | 0.79 | 0.85 | 0.00 | -0.08 | -0.15 |
| EPS Diluted | -1.77 | 1.21 | -0.05 | -0.18 | -0.26 |
| Normalized Diluted EPS | 0.76 | 0.82 | 0.00 | -0.08 | -0.15 |
| Average Basic Shares Outstanding | 872.92M | 839.55M | 835.96M | 832.69M | 829.59M |
| Average Diluted Shares Outstanding | 901.29M | 874.30M | 862.41M | 849.43M | 835.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |